Latest Industry Insights

In this week's instalment of "Technology Networks Explores the CRISPR Revolution", we're focusing on the technical elements of CRISPR technology. Helping us to answer key questions in this space is Dr Amy Butler, President of the Biosciences Division at Thermo Fisher Scientific.

We recently spoke with Daniel Berman, Global Health Lead at Nesta Challenges, to learn about the Longitude Prize, a £10 million prize fund with an £8 million pay-out, which will be awarded to a team that invents an affordable, accurate, fast and easy-to-use test for bacterial infections.

We spoke to Daniel Rooke, Head of Operations and Legal at Start Codon, to learn more about the company and how they can help early stage healthcare and life science businesses in the UK to get off the ground.

We recently had the pleasure of interviewing Paul-Peter Tak, CEO of Kintai Therapeutics. Tak discusses how Kintai Therapeutics are exploiting the power of big data and machine learning to unravel the interconnected biology of the gut, and explains how the enteric signaling network can be therapeutically targeted.

Neurodegenerative diseases are one of the most pressing challenges of our time and teasing out the cellular mechanisms underpinning these diseases is a key goal for researchers in the field. We talked to Stéphane Martinez of CISBIO to discuss how researchers can access information on neurodegenerative mechanisms and how we are beginning to recognize the contribution of the immune system to neurodegeneration.

Aided by advances in high-throughput technologies, the metabolomics research field has gained significant traction. We spoke with Baljit Ubhi, Ph.D. from SCIEX, about the recent developments in metabolomics, addressing the increasing focus on the microbiome, how it impacts metabolic disease, and the future directions of research, including "precision nutrition".

To learn how Campylobacter hides from the body’s immune system, why some people are more susceptible than others, and the potential role that carbohydrate-based diagnostics could play in the fight against the bacterium, we spoke to Professor Rob Field, Co-founder of Iceni Diagnostics.

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

Fluid Imaging Technologies and the University of Colorado Boulder have recently entered an exclusive research agreement to determine whether the University’s artificial intelligence software can identify bloodborne bacteria. We spoke with Kent Peterson, CEO, Fluid Imaging Technologies, to learn more about the collaboration, the technologies involved, and how they could impact patients.

Microscopy is a key tool in many areas of research, but what happens when what you want to study is in a remote location, doesn’t transport well or you need instant answers? Well, then the analysis has to go to the sample. We spoke to Andrew Monk, cofounder of ioLight, about ioLight’s conception and what makes it so special.